PROGRESSION OF AORTIC AND VALVULAR HEART DISEASES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Involvement of the aorta and heart valves in ankylosing spondylitis (AS) is a manifestation of the systemic inflammatory process. Data on the frequency, clinical significance, and evolution of these manifestations are controversial.

Objective: to estimate the time course of echocardiographic (EchoCG) changes in the aorta and heart valves from the results of a prospective follow-up study of patients with AS.

Subjects and methods. In 2008 to 2015, the V.A. Nasonova Research Institute of Rheumatology followed up 45 patients (35 men and 10 women) with documented AS that was consistent with the modified New York criteria and the original EchoCG changes in the aorta and heart valves. All the patients underwent transthoracic echocardiography at baseline and after 1–5 years. At baseline, there was aortic root dilatation (>37 mm) in 15 patients, thickening of the aortic walls and aortic valve (AV) cusps in 21 and 32 patients, respectively, as well as thickening of the mitral valve (MV) cusps in 15, and valve prostheses in 5 patients (2 had AV and MV prostheses). Aortic regurgitation (AR) was recorded in 19 patients (grades 1–2 AR in 15 patients and grades 3–4 in 4 patients); grades 1–2 mitral regurgitation (MR) was seen in 20 patients. Ten patients had subaortic pectinate thickening (SPT) in the aortomitral junction area. Of the 45 patients, 16 took biological agents (BA); 29 received traditional therapy, including 14 patients who used nonsteroidal anti-inflammatory drugs, 11 and 4 patients had sulfasalazine and methotrexate, respectively.

Results and discussion.Repeated examinations revealed negative changes in 27 (60%) of the 45 patients. Progressive aortic dilatation (1 to 6 mm) was found in 12 (80%) of the 15 patients; dilatation appeared during follow-up in 2 patients. Fourteen patients were noted to have negative valve changes: the emergence of cusp thickening in the valves (that in AV and MV in 9 and 4 patients, respectively; both in 1 patient). Four patients underwent valve replacement: 3 and 1 patients underwent AV and MV replacements, respectively. Ten of the 19 patients were observed to have AR progression by 2 grades in 2 (10.5%) patients and by one grade in 8 (42.0%) patients. MR progression by one grade was noted in 6 (30.0%) of the 20 people. A negative correlation was found between BA therapy and aortic dilation progression (r = -0.329; p = 0.03). SPT appeared in 3 patients. Of the 10 patients who had a baseline SPT, its reduction (8 to 3.5 mm) was seen in one patient; complete regression was identified in two patients; all received BAs. Thus, pathological changes in the aorta and heart valves in AS are progressive in most patients. SPT may regress, which reflects apparently a reduction in the severity of active inflammation of the aortic root. Active anti-inflammatory treatment may play a protective role in the progression of aortic dilatation.

1. Bergfeldt L. HLA-B27-associated Cardiac Disease. Ann Intern Med. 1997;127(8 Pt1):621-9. doi: 10.7326/0003-4819-127-8_Part_1-199710150-00007

2. Bruges-Armas J, Lima C, Simas Lopes C. HLA-B27 in patients with a permanent pacemaker. Ann Rheum Dis. 2003;62:1018. doi: 10.1136/ard.62.10.1018

3. Годзенко АА, Бочкова АГ, Корсакова ЮО и др. Поражение сердца при анкилозирующем спондилите. Научно-практическая ревматология. 2009;47(4):4-10 [Godzenko AA, Bochkova AG, Korsakova YuO, et al. Heart damage in ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(4):4-10 (In Russ.)]. doi: 10.14412/1995-4484-2009-1144

4. Moyssakis I, Gialafos E, Vassiliou VA, et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand J Rheumatol. 2009;38(3):216-21. doi: 10.1080/03009740802474672

5. Lautermann D, Braun J. Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol. 2002;20(6 Suppl 28):511-5.

6. Roldan CA, Chavez J, Wiest PW. Aortic root disease and valve disease, associated with ankylosing spondylitis. J Am Col Cardiol. 1998;32(5):1397-404. doi: 10.1016/S0735-1097(98)00393-3

7. Arnason JA, Patel AK, Rahko PS, Sundstrom WR. Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. J Rheumatol. 1996;23:120-3.

8. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart cardiac do conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population. Clin Rheumatol. 2006 Feb;25(1):24-9. Epub 2005 Oct 25. doi: 10.1007/s10067-005-1117-6

9. Heslinga S, Konings T, Kamp O, et al. High prevalence of cardiac disease in patients with ankylosing spondylitis. 2015 ACRARHR Annual Meeting. September 29, 2015.

10. Klingberg E, Sveä lv BG, Tä ng MS, et al. Aortic regurgitation is common in ankylosing spondylitis: Time for routine echocardiography evaluation? Am J Med. 2015 Nov;128(11):1244-50. doi: 10.1016/j.amjmed.2015.04.032. Epub 2015 Jun 4.

11. Park So-Hee, Sohn Il-Suk, Joe Byung-Hyun, et al. Early cardiac valvular changes in ankylosing spondylitis: A transesophageal echocardiography study. J Cardiovasc Ultrasound. 2012 Mar;20(1):30-6. doi: 10.4250/jcu.2012.20.1.30

12. Bergfeldt L, Edhag O, Vallin H. Cardiac conduction disturbances, an underestimated manifestation in ankylosing spondylitis. A 25-year follow-up study of 68 patients. Acta Med Scand. 1982;212:217-23. doi: 10.1111/j.0954-6820.1982.tb03203.x

13. Bergfeldt L, Insulander P, Lindblom D, et al. HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med. 1988;85:12-8. doi: 10.1016/0002-9343(88)90497-4

14. Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal to modification of the New York criteria. Arthritis Rheum. 1984;27:361-8. doi: 10.1002/art.1780270401

15. www.ASAS-group.org

16. Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007 Aug;66(8):1072-7. doi: 10.1136/ard.2006.064543

17. Essers I, Ramiro S, Stolwijk C, et al. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clin Exp Rheumatol. 2016 Mar– Apr;34(2):214-21.

18. Zarco P, Gonzalez CM, Rodriguez de la Serna A. Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. Reumatol Clin. 2015 Mar-Apr;11(2):83-9. doi: 10.1016/j.reuma.2014.04.003